GÖTTINGEN, Germany,
July 2, 2021 /PRNewswire/ -- The life
science group Sartorius, through its subgroup Sartorius Stedim
Biotech, has acquired a majority stake in the reagent manufacturer
CellGenix GmbH. The company based in Freiburg, Germany, and with a sales subsidiary near the
biotechnology hub in Boston,
Massachusetts USA, produces and markets cell culture
components, such as growth factors, cytokines and media in GMP
quality for manufacturing cell and gene therapy products.
Sartorius has initially acquired 51 percent of this company,
which has been privately owned until now, for around
100 million euros in cash. At the beginning of 2023 and
2026, Sartorius plans to acquire the remaining shares of CellGenix.
Founded in 1994 at the University Medical Center of Freiburg,
CellGenix currently employs some 70 people and generated sales of
more than 20 million euros in 2020, achieving a very
significant double-digit EBITDA margin.
"CellGenix has an excellent reputation on the market and brings
in high technological expertise and considerable regulatory
experience in one of the fastest-growing fields of the biopharma
sector. Together, we will support our customers even better in
fast-tracking their drug candidates efficiently through the various
steps in the development of medicines so that innovative therapies
can reach patients faster," said René Fáber, member of the
Executive Board for the Bioprocess Solutions Division of
Sartorius.
"For us, Sartorius is an ideal partner with a highly
complementary product portfolio that will accelerate our
development with its global sales team, enabling us to usher in our
next phase of growth," added Felicia Rosenthal, CEO and
co-founder of CellGenix.
Sartorius plans to expand the Freiburg site substantially and to
establish it as a center of excellence within the group in the
areas of development and manufacture of quality critical raw
materials for the cell and gene therapy market.
This press release contains forward-looking statements about the
future development of the Sartorius Group. Forward-looking
statements are subject to known and unknown risks, uncertainties
and other factors that could cause actual results to differ
materially from those expressed or implied by such statements.
Sartorius assumes no liability for updating such statements in
light of new information or future events. This is a translation of
the original German-language press release. Sartorius shall not
assume any liability for the correctness of this translation. The
original German press release is the legally binding version.
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2020, the company earned sales revenue of
some 2.34 billion euros. At the end of 2020, nearly 11,000
people were employed at the Group's approximately
60 manufacturing and sales sites, serving customers around the
globe.
Contact
Petra Kirchhoff
Corporate Communications & Investor Relations
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
sartorius.com
Follow Sartorius on Twitter @Sartorius_Group and on
LinkedIn.
View original
content:https://www.prnewswire.com/news-releases/sartorius-strengthens-product-portfolio-for-cell-and-gene-therapies-by-acquiring-a-majority-stake-in-cellgenix-301324920.html
SOURCE Sartorius AG